Novo Nordisk A/S (NYSE:NVO) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Novo Nordisk A/S (NYSE:NVO) have earned a consensus rating of “Hold” from the twenty-three research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, eighteen have assigned a hold rating and four have given a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $65.5625.

NVO has been the topic of several recent research reports. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, May 12th. Morgan Stanley upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price for the company in a report on Tuesday, March 3rd. Finally, Wall Street Zen raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Longer-term bulls point to Novo Nordisk as one of the more undervalued foreign pharma names, with recent strong earnings and guidance supported by demand for its Wegovy weight-loss pill. Novo Nordisk (NVO) Among Our Most Undervalued Foreign Stocks to Buy Now
• Neutral Sentiment: Analysts at Deutsche Bank reportedly kept a hold rating and DKK290 target after Novo discussed its oral semaglutide launch, but noted dose-escalation patterns are not yet matching the company’s injectable GLP-1 products. Novo Nordisk faces complex GLP-1 landscape as oral launch patterns diverge from injectables
• Neutral Sentiment: Broader coverage changes at CVS for Eli Lilly’s Zepbound and Foundayo highlight how quickly the obesity-drug market is shifting, with both Lilly and Novo Nordisk products now competing for preferred coverage. CVS Caremark adds Zepbound and Foundayo to formulary
• Negative Sentiment: CVS Caremark’s restored coverage for Eli Lilly’s Zepbound improves access for Lilly and intensifies competition in obesity treatments, which may weigh on Novo Nordisk’s growth expectations in the GLP-1 category. CVS Restores Coverage for Lilly’s Zepbound

Institutional Trading of Novo Nordisk A/S

Large investors have recently modified their holdings of the business. Guerra Advisors Inc purchased a new stake in Novo Nordisk A/S in the 3rd quarter worth approximately $25,000. Godfrey Financial Associates Inc. bought a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $25,000. Strengthening Families & Communities LLC bought a new position in shares of Novo Nordisk A/S during the third quarter valued at approximately $30,000. WealthCollab LLC lifted its stake in Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after acquiring an additional 260 shares during the period. Finally, American National Bank & Trust bought a new stake in Novo Nordisk A/S in the fourth quarter valued at $28,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Up 0.1%

NVO opened at $45.57 on Friday. The business’s fifty day simple moving average is $40.98 and its 200 day simple moving average is $46.37. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $81.44. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The stock has a market cap of $203.49 billion, a PE ratio of 10.70, a P/E/G ratio of 4.06 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The company had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. As a group, research analysts expect that Novo Nordisk A/S will post 3.46 earnings per share for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.